Anti-TFPI for hemostasis induction in patients with rare bleeding disorders, an ex vivo thrombin generation (TG) guided pilot study.

[1]  J. Mahlangu.  Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management , 2021, Frontiers in Medicine.

[2]  W. Ouwehand,et al.  Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency. , 2021, Blood advances.

[3]  M. Díaz-Ricart,et al.  Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid: experimental studies in thromboelastometry , 2020, Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine.

[4]  Michael Wang,et al.  2021 clinical trials update: Innovations in hemophilia therapy , 2020, American journal of hematology.

[5]  G. Kenet,et al.  Emicizumab treatment and monitoring in a paediatric cohort: real‐world data , 2020, British journal of haematology.

[6]  P. Mannucci.  Hemophilia therapy: the future has begun , 2020, Haematologica.

[7]  G. Kenet,et al.  Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction. , 2020, Blood cells, molecules & diseases.

[8]  K. Downes,et al.  Investigation of patients with unclassified bleeding disorder and abnormal thrombin generation for physiological coagulation inhibitors reveals multiple abnormalities and a subset of patients with increased tissue factor pathway inhibitor activity , 2020, International journal of laboratory hematology.

[9]  R. Sidonio,et al.  TFPI blockade: removing coagulation's brakes. , 2019, Blood.

[10]  John E. Murphy,et al.  Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  F. Peyvandi,et al.  Treatment of rare factor deficiencies other than hemophilia. , 2019, Blood.

[12]  V. Jiménez‐Yuste,et al.  Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  G. Young,et al.  Thromboelastography and thrombin generation assay in inherited afibrinogenemia , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  G. Kenet,et al.  Alternative treatment options for pediatric hemophilia B patients with high‐responding inhibitors: A thrombin generation‐guided study , 2018, Pediatric blood & cancer.

[15]  S. Arkin,et al.  A first‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐06741086, an anti‐tissue factor pathway inhibitor mAb, in healthy volunteers , 2018, Journal of thrombosis and haemostasis : JTH.

[16]  G. Kenet,et al.  Rare bleeding disorders-old diseases in the era of novel options for therapy. , 2017, Blood cells, molecules & diseases.

[17]  S. Lethagen,et al.  Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial , 2015, Journal of thrombosis and haemostasis : JTH.

[18]  A. Mast,et al.  Biology of tissue factor pathway inhibitor. , 2014, Blood.

[19]  P. Mannucci,et al.  Alloantibodies in von Willebrand disease. , 2013, Blood.

[20]  Bin Zhang,et al.  Combined Deficiency of Coagulation Factors V and VIII: An Update , 2013, Seminars in Thrombosis & Hemostasis.

[21]  J. Rosing,et al.  Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. , 2008, Blood.

[22]  A. Girolami,et al.  Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  D. Steinberg,et al.  Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. , 2003, Blood.

[24]  F. Rosendaal,et al.  Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. , 2003, Blood.

[25]  Kenneth G. Mann,et al.  Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II* , 1997, The Journal of Biological Chemistry.

[26]  M. T. Madsen,et al.  Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[27]  A. Mast.  Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein. , 2016, Arteriosclerosis, thrombosis, and vascular biology.